1. Inhibitory Antibodies
  2. Biosimilar Antibodies
  3. Monoclonal Antibodies
  4. Edrecolomab

Edrecolomab  (Synonyms: Panorex; CO17-1A)

Cat. No.: HY-P99231 Purity: 98.63%
Data Sheet Technical Support

Edrecolomab (Panorex) is a murine monoclonal antibody to the cell-surface glycoprotein 17-1A, expressed on epithelial tissues and on various carcinomas. Edrecolomab shows anti-tumor activity and can be used in colorectal carcinoma research.

For research use only. We do not sell to patients.

CAS No. : 156586-89-9

Size Price Stock Quantity
1 mg USD 280 In-stock
5 mg USD 700 In-stock
10 mg USD 1120 In-stock
50 mg   Get quote  
100 mg   Get quote  

Get it by April 8 for select sizes. Order within 10 hrs 9 mins.

* Please select Quantity before adding items.

Customer Review

Based on 1 publication(s) in Google Scholar

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Edrecolomab (Panorex) is a murine monoclonal antibody to the cell-surface glycoprotein 17-1A, expressed on epithelial tissues and on various carcinomas. Edrecolomab shows anti-tumor activity and can be used in colorectal carcinoma research[1][2].

Isotype

Mouse IgG2a kappa

Recommend Isotype Controls
Species

Mouse

In Vitro

Edrecolomab (0-100 μg/mL; 20 h) shows moderate antibody-dependent cellular cytotoxicity (ADCC)[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay[1]

Cell Line: KATO III cells
Concentration: 0-100 μg/mL
Incubation Time: 20 hours
Result: Exhibited an ED50 value>100 ng/ml.
In Vivo

Edrecolomab (intravenous injection; 30 μg/dose; day 1, 4 and 7 after tumor-cell inoculation) treatment inhibits tumor growth in the HT-29 nude mouse model[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male nu/nu mice injected with HT-29 colon carcinoma cells[1]
Dosage: 30 μg/dose
Administration: Intravenous injection; 30 μg/dose; day 1, 4 and 7 after tumor-cell inoculation
Result: Inhibited tumor growth with a number of significant readings (p≤0.05).
Clinical Trial
NCT NumberSponsorConditionStart DatePhase
NCT00002968National Cancer Institute (NCI)
Mucinous Adenocarcinoma of the Colon|Signet Ring Adenocarcinoma of the Colon|Stage IIA Colon Cancer|Stage IIB Colon Cancer|Stage IIC Colon Cancer
May 1997Phase 3
NCT00002664James Ahlgren|George Washington University
Colorectal Cancer
July 1995Phase 2
CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Edrecolomab]

Shipping

Shipping with dry ice.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Format
  • IgG2a-kappa
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Edrecolomab
Cat. No.:
HY-P99231
Quantity:
MCE Japan Authorized Agent: